We are live on ! Find out more
NFGH

Nan Fung Group Holdings Portfolio holdings

AUM $121M
1-Year Est. Return 56.89%
This Fund
S&P 500
This Quarter Est. Return
-14.23%
1 Year Est. Return
+56.89%
3 Year Est. Return
+244.35%
5 Year Est. Return
+210.19%
10 Year Est. Return
–
AUM
$146M
AUM Growth
-$65.3M
Cap. Flow
-$17.1M
Cap. Flow %
-11.73%
Top 10 Hldgs %
82.35%
Holding
48
New
3
Increased
1
Reduced
5
Closed
7

Top Buys

Rank Stock Value
1
SNOW icon
Snowflake
SNOW
+$3.04M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$2.98M
3
REPL icon
Replimune Group
REPL
+$1.33M
4
HCP
HashiCorp, Inc. Class A Common Stock
HCP
+$524K

Top Sells

Rank Stock Value
1
HRMY icon
Harmony Biosciences
HRMY
+$5.98M
2
VIR icon
Vir Biotechnology
VIR
+$5.42M
3
BEAM icon
Beam Therapeutics
BEAM
+$3.15M
4
ILMN icon
Illumina
ILMN
+$2.74M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$2.53M

Sector Composition

Rank Sector Weight
1 Healthcare 97.27%
2 Technology 2.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMRN icon
26
BioMarin Pharmaceuticals
BMRN
$12.4B
$507K 0.35%
6,115
– –
ACAD icon
27
Acadia Pharmaceuticals
ACAD
$5.03B
$422K 0.29%
29,984
– –
ARGX icon
28
argenx
ARGX
$54.1B
$421K 0.29%
1,110
– –
ASND icon
29
Ascendis Pharma A/S
ASND
$16.8B
$387K 0.27%
4,168
– –
HCP
30
DELISTED
HashiCorp, Inc. Class A Common Stock
HCP
$383K 0.26%
+13,001
New +$524K
ALXO icon
31
ALX Oncology
ALXO
$290M
$339K 0.23%
41,950
– –
SRPT icon
32
Sarepta Therapeutics
SRPT
$1.77B
$294K 0.2%
3,917
– –
RETA
33
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$251K 0.17%
8,265
– –
AFMD
34
DELISTED
Affimed
AFMD
$225K 0.15%
8,117
– –
KYNB
35
Kyntra Bio
KYNB
$29.4M
$156K 0.11%
590
– –
KOD icon
36
Kodiak Sciences
KOD
$2.84B
$150K 0.1%
19,622
– –
ABCL icon
37
AbCellera Biologics
ABCL
$2.12B
$133K 0.09%
12,521
– –
SYBX
38
DELISTED
Synlogic
SYBX
$79K 0.05%
4,576
– –
CERS icon
39
Cerus
CERS
$474M
$75K 0.05%
14,172
– –
TCRR
40
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$56K 0.04%
19,335
– –
NVTA
41
DELISTED
Invitae Corporation
NVTA
$28K 0.02%
11,337
-144,667
-93% -$640K
BEAM icon
42
Beam Therapeutics
BEAM
$2.84B
– –
-54,903
Closed -$3.15M
DAWN
43
DELISTED
Day One Biopharmaceuticals
DAWN
– –
-11,445
Closed -$114K
DYN icon
44
Dyne Therapeutics
DYN
$4.9B
– –
-11,629
Closed -$112K
EXAS
45
DELISTED
Exact Sciences
EXAS
– –
-17,464
Closed -$1.22M
VIR icon
46
Vir Biotechnology
VIR
$1.49B
– –
-210,563
Closed -$5.42M
RUBY
47
DELISTED
Rubius Therapeutics, Inc
RUBY
– –
-56,768
Closed -$313K
SRRA
48
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-52,979
Closed -$1.7M
1
2

Similar funds

MAM
Mirabaud Asset Management London, United Kingdom $121M AUM 20.69% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
CCM
Candelo Capital Management New York $121M AUM 113.39% 1-Year Est. Return
CCM
CFO Capital Management Fairfield, Connecticut $121M AUM
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
RIP
Reliant Investment Partners Pinehurst, North Carolina $121M AUM 34.77% 1-Year Est. Return
CF
Conquis Financial Milbrae, California $121M AUM 16.22% 1-Year Est. Return
MW
Merited Wealth North Bay Village, Florida $121M AUM

Nan Fung Group Holdings's Q2 2022 Portfolio in Review

As of Q2 2022, Nan Fung Group Holdings held 48 positions worth $146M, down 31% from $211M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Nan Fung Group Holdings withdrew a net $17.1M in Q2 2022, closing 7 positions and reducing 5 holdings. Its most notable exit was Vir Biotechnology, an estimated $5.42M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 99% a quarter earlier, followed by Technology.

Against the trend, Nan Fung Group Holdings opened a new position in Snowflake worth $2.67M.

  • Nan Fung Group Holdings's largest Q2 2022 buy was Snowflake: 19,210 shares worth $2.67M.
  • Nan Fung Group Holdings added most to Replimune Group in Q2 2022, an estimated $1.33M increase.
  • Nan Fung Group Holdings's biggest Q2 2022 reduction was Harmony Biosciences, cutting an estimated $5.98M.
  • Nan Fung Group Holdings fully exited Vir Biotechnology in Q2 2022, selling an estimated $5.42M.
  • Nan Fung Group Holdings's ten largest holdings make up 82% of its $146M portfolio in Q2 2022.
  • Nan Fung Group Holdings opened 3 new positions and closed 7 in Q2 2022.
  • Nan Fung Group Holdings's portfolio value fell 31% quarter-over-quarter to $146M.

Based on Nan Fung Group Holdings's 13F filing for Q2 2022, filed 12 Aug 2022.